Episode 69 · May 7, 2026 · 40m listen · 8,106 words · ~41 min read

Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital | Ep. 69 - Full Transcript | The Med Device Cyber Podcast

Read the complete, searchable transcript of Episode 69 of The Med Device Cyber Podcast - expert conversations on medical device cybersecurity, FDA premarket and postmarket guidance, SBOM management, threat modeling, and penetration testing.

Prefer the listening experience? Open the episode page for the synopsis, key takeaways, topics, and Apple / YouTube listen links.

Episode summary

In this episode of the MedDevice Cyber podcast, host Christian Espinosa welcomes Varun Turlapati, Managing Director of Chaanakya Capital, an early-stage venture capital firm specializing in Neurotech and MedTech. Varun, whose background is in software engineering, explains that his firm focuses on pre-seed to Series A investments in companies developing genuine, science-backed medical technology. He draws a sharp distinction between legitimate, medically grounded devices and what he terms "sham devices"—products that might gain traction and quick financial returns but lack scientific validity. Chaanakya Capital's investment philosophy is rooted in finding companies that solve real-world clinical problems, with a strong emphasis on the underlying science and a viable economic model that considers regulatory and reimbursement pathways. A significant portion of the discussion revolves around the critical importance of cybersecurity in the medical device sector. Both Varun and Christian stress that cybersecurity cannot be an afterthought. Christian argues that a modest upfront investment in expert cybersecurity consulting can save startups hundreds of thousands of dollars in rework and prevent major headaches down the line. He points out that poor early-stage decisions, such as choosing hardware that doesn't support necessary security requirements, can force companies to roll back features and incur significant costs. Varun builds on this by highlighting the dramatically higher stakes in MedTech compared to other industries like B2B SaaS. While a hack in a software company might result in data loss, a compromised medical device could lead to a loss of life, making robust security non-negotiable. Varun also shares his passion for the neurotech field, stating that humanity's understanding of the brain is still in its infancy compared to our knowledge of deep space or ocean mining. He is motivated by the potential to advance treatments for complex neurological conditions such as Alzheimer's, Parkinson's, and the effects of stroke, offering alternatives to pharmaceuticals. He discusses his firm's approach to due diligence, which now includes a strong focus on a company's cybersecurity plan. Varun's vision is to not only generate returns but also to create a meaningful impact by supporting innovations that advance the human condition, starting with a deeper understanding and treatment of the brain.

Key takeaways from this episode

Investing in Neurotech and MedTech requires prioritizing genuine, medically-grounded science and clinical applications over speculative or 'sham' products that may promise quick profits.
Early-stage medical device companies must integrate cybersecurity into their design and development process from the very beginning to avoid costly rework and critical vulnerabilities.
A small, early investment in cybersecurity consulting can save companies hundreds of thousands of dollars by preventing poor architectural decisions, such as choosing incompatible hardware.
The stakes for cybersecurity in medical devices are far higher than in other software industries; a hack can directly lead to patient harm or loss of life.
Humanity's understanding of the brain is still a major frontier for scientific discovery, with significant opportunities for technological innovation.
Investors in specialized, high-impact fields like Neurotech should be active partners, offering expertise and being readily available to help founders navigate complex challenges.
In the age of AI and IoT, every connected device, no matter how small, is a potential target for hacking, making security a universal concern.
The primary criteria for investment in MedTech should be the strength of the medical science, engineering, and the plan for navigating regulatory and reimbursement pathways.

Full episode transcript

Guest: I think as humanity, we don't understand our brain nearly as well as we may understand deep space mining and deep ocean mining and things that are way out there, we still don't understand what's between our years as much, right? There could be a sham device for example, like hey, just wear this ring and you do better on your day-to-day tasks. And it may pick up traction. Guest: company can exit 100x in 3 to 5 years. But that is not good for us. We are trying to go back genuine science and tech and medically grounded devices. Host: a little bit of consulting time with some experts like Blue Goat Cyber can save you a lot of money and headache down the road. You know, like our consulting might cost $5,000, but if they don't talk to us and make all these decisions later on, they may end up spending $500,000 in rework and have to roll back some of the features because they could have chose a piece of hardware that doesn't support the right cybersecurity requirements. Guest: we should also bring in the cybersecurity aspect. Now more than ever. when I say now, it's like in the age of AI, age of like this, everything and everyone is online, the smallest of the devices is on network and can be hacked into. We would be grossly underestimating the impact. Guest: Like losing a customer in a B2B SaaS case, the worst case is like, yeah, sure, a lawsuit and like whatever, some data loss or something of that sort which sounds serious, but hey, a loss of life because of a hack is worse. Host: Hi, welcome to the Med Device Cyber podcast. Today we have an investor, Varun, joining us. And where are you coming from today, Varun, actually? Guest: Dialing in from San Francisco Bay Area. Host: San Francisco. That's where our COO typically has base, but he had to travel to a client site for an FDA audit. Otherwise he would be here today as well. So it's just going to be me as the host, our co-host Trevor is not going to be here. Why don't you tell us a little bit about what you do in MedTech? I know you're an investor. I know we've met you at quite a few of the MedTech World events. I think is where we first met. Guest: Yeah, definitely. Well, first we met was uh last year at LSI Asia. That was the flagship, the first ever LSI Asia, I suppose. That's where we first met. But then after that, you're right, also MedTech World events as well. Guest: We are an early-stage NeuroTech VC, or put in other words, neuro focused MedTech VC. Early stage for us is anywhere from pre-seed to Series A even. Uh, it's more a function of the valuation uh as of when we invest rather than the name of the round itself. Guest: And, you know, in a in a span of a year, actually, I think today or tomorrow, we will turn one year as a fund. We have four portfolio companies and we have capital that we are looking to deploy into three more in the upcoming quarter because we have already been diligencing a few companies. And so we're very excited about this space. Host: What are some of the main things you look for when you decide to invest in a company, a MedTech innovator? Guest: Yeah, so the first and foremost is the science and the technology itself. You know, what is the problem that is being solved here? You know, it should make sense that here's a problem and here is what maybe an existing solution has been and here is how we are trying to do it. So I think a lot of it grounded on that. Guest: In the space that we are in, there tend to be a lot of claims that we need to be very careful about. You know, hey, we want to do this, we want to do that. The ambition might be good to have, but where the company is at currently and is it, is the trajectory good enough in the way they're explaining things? Have they thought through? is the first and foremost thing, right? Without the science and the tech, the economics may make sense. What I mean by that is, there could be a sham device, for example, like, hey, just wear this ring and you'd be, you'd do better on your day-to-day tasks. Guest: And it may pick up traction. You know, you could do a crowdfunding or even without that, you may have VCs investing and, you know, things people believe it and athletes are advertising it and so on, great. And so near term, this company can exit, you know, 100x in three to five years.

1 / 9